Search Results

and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases biomarker and a new target for diabetes and that CXCR2 antagonists may also attenuate lung injury in coronavirus disease 2019 (COVID-19). " Authors Yishi Xie , Wenbin Kuang , Dawei Wang , Kai Yuan , Peng Yang Tags CXCR2 , CXCR2 antagonist , Cancer , Chronic obstructive pulmonary disease (COPD) , Coronavirus disease 2019 (COVID-19) , Inflammatory disease.

In particular, the association of the disease with several types of anti-G protein-coupled receptor ( To date, POTS is recognized as one of the sequelae of coronavirus disease 2019 (COVID-19) and its frequency Multiple autoantibody types occur in COVID-related, autonomic disorders, suggesting the presence of autoimmune

Oncology and Immunology Increased protease-activated receptor 1 autoantibodies are associated with severe COVID -19 Published date December 27, 2022 Abstract In patients with severe #COVID19 , increased levels of endothelial cells and platelets, and thus might contribute to the pathogenesis of microthrombosis in COVID -19.

GPCRs in Oncology and Immunology Protease-Activated Receptor-1 IgG Autoantibodies in Patients with COVID -19 Published date December 1, 2024 Abstract "No abstract available" Authors Leander Reinshagen, Vanasa

< GPCR News < GPCRs in Oncology and Immunology Coronavirus Porcine Epidemic Diarrhea Virus Utilizes Chemokine However, the effect of chemokine on epithelia and how chemokine is involved in coronavirus infection Here, we identified an inducible chemokine interleukin-8 (CXCL8/IL-8), which could promote coronavirus IMPORTANCE Coronavirus porcine epidemic diarrhea virus (PEDV) is a highly contagious enteric coronavirus and more effort is needed to develop economical and efficient vaccines to control or eliminate this disease

and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases David Siderovski and Vincent Setola (2014-2019). Marc Caron (2019-2023) and subsequently, will begin my independent research career as a tenure-track novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases

< GPCR News < GPCRs in Oncology and Immunology Deciphering the genetic landscape of lumpy skin disease through comprehensive genome sequence analysis in India Published date May 23, 2024 Abstract "Lumpy Skin Disease (LSD), a poxvirus disease affecting cattle, emerged in India in 2019 and intensified in 2022, resulting A comprehensive genetic study conducted, analyzing samples from 2019 to 2022 revealed circulation of in the Functional Resolution Sequence (FRS) repeats of LSDV genomes from 2022 outbreaks, absent in 2019

during prolonged cold exposure Anastasia Georgiadi ADGRF5-mediated regulation of cardiac health and disease Netherlands; 2Department of Experimental Immunology, Amsterdam institute for Immunology and Infectious diseases -2015: PhD in Immunology, University of Amsterdam; 2015-2019: Postdoctoral researcher, Amsterdam UMC; 2019-2022: Senior postdoctoral researcher, Netherlands Institute for Neuroscience; 2022 - present: Researcher Georgiadi on the web Endocrine Pharmacology Google Scholar ADGRF5-mediated regulation of cardiac health and disease

importantly, the GPCR Retreat dedicates time for two trainee symposia, an initiative that began in the Ottawa 2017 For the Ottawa 2017 GPCR Retreat, of the ten talks from trainees 80% were from women and 60% from visible The past few GPCR retreats have been held in : Niagara-on-the-lake (2022) Bromont, Québec (2019) Detroit , Michigan (2018) Ottawa, Ontario (2017) Chicago, Illinois (2016) Toronto, Ontario (2015) Bromont, Québec (2014) Cleveland, Ohio (2013) London, Ontario (2012)

News < GPCRs in Oncology and Immunology Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID This observational study aims to evaluate the efficacy of IA in patients with post-COVID-19 ME/CFS. Due to the urgency of finding therapies for post-COVID-Syndrome (PCS), we report here the interim results Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , SF-36 , autoantibodies , immunoadsorption , long COVID , physical function , post-COVID syndrome Source Contribute to the GPCR News Coming soon Become a Contributor

News < GPCRs in Oncology and Immunology GPCRs and fibroblast heterogeneity in fibroblast-associated diseases About one-third of the commercially available drugs for various diseases target the GPCRs. Understanding the dynamics of GPCR signaling in fibroblasts with disease progression can help in the recognition of the complex interplay of different GPCR subtypes in fibroblast-mediated diseases. Apar K Ganti , Surinder K Batra , Maneesh Jain Tags GPCR signaling , fibroblast behavior , fibrotic diseases

Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in 2015 gained experience in the identification and characterization of llama-derived antibodies in inflammatory diseases From 2015 to 2019, he completed his Ph.D. in the Medicinal Chemistry group at VU University Amsterdam conformations, while also focusing on their therapeutic potential in oncology and transplant infectious disease Starting from September 2019, Timo started working as a postdoctoral researcher at the Vrije Universiteit

This axis is linked to diseases like HIV/SIV, cancer, and COVID-19. CXCR6 in chickens may have altered CD8 TRM cell abundance, with implications for immunity against viral diseases

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases

< GPCR News < GPCRs in Oncology and Immunology Severity of neurological long-COVID symptoms correlates autonomic nervous system receptors Published date September 7, 2023 Abstract "Background: The Long-COVID The pathogenesis of Long-COVID is currently under heavy scrutiny and existing data on the role of auto-immune moderate SARS-CoV-2 infection up to 12 months prior to enrollment with (n = 72) or without (n = 58) Long-COVID Results: The prevalence and concentrations of evaluated autoantibodes were significantly higher in Long-COVID

, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with Pandemic Journey and Global Challenges Yamina and Arthur discussed Arthur's experiences during the Covid personal health struggles, the growth of his university, and the faculty's successful response to the Covid

, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with Pandemic Journey and Global Challenges Yamina and Arthur discussed Arthur's experiences during the Covid personal health struggles, the growth of his university, and the faculty's successful response to the Covid

Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has

We also touched on how COVID-19 affected her Ph.D. work.

Sponsors GPCR Retreat Program < Back to schedule Genetic Deletion of Atypical VGLUT3 Rescues Huntington’s Disease coupled receptors and their role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases

Ph.D. in Life Sciences from the University of Lausanne, Switzerland, Department of Biochemistry (2005-2009 crucial role of the lipidic environment on their structure and function during my post-doctoral work (2010 -2015). In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

In 1983, he joined the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the His numerous awards include: 2008 Sato Award; 2009 Medicinal Chemistry Hall of Fame (American Chemical Soc.); 2014 Goodman and Gilman Award; 2017 Tu Youyou Award; 2017 Smissman Award; 2023 Hershberg Award

Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases The consequences of altered neuroimmune activity differ with tissue type and disease and include: skin neuroimmune interactions that underlie the various sensory and autonomic pathologies in type 2 inflammatory diseases in targeted treatment approaches to reduce type 2 inflammation and its associated symptoms in these diseases CSU , Calcitonin gene-related peptide , Chronic idiopathic urticaria , Chronic obstructive pulmonary disease

Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune System, and Western Diseases pro-inflammatory immune cells may travel to tissues such as the brain, the lung, the kidney etc and promote disease how the gut microbiome may be affecting peripheral immune cells, and consequently Western lifestyle diseases Authors Quanbo Wang , Charles R Mackay Tags Gut microbiota , Western lifestyle diseases , portal vein

Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure to animal models of disease

the Royal Society of Edinburgh in 1998 and to the Fellowship of the Academy of Medical Sciences in 2016 Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments

Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009 William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis In 2015, He joined Dr. in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases

limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID -19 vaccines, is emerging as a promising method for antibody discovery.